Close Menu

cell-free DNA

The firm, a University of Edinburgh spinout, will use the funding to in-license its BioCollector liquid biopsy platform and launch initial trials. 

The company is planning to commercialize its cancer early detection technology initially in lung cancer and is working with NYU researchers to explore future expansions.

The startup will use the funds to support R&D and to launch its Qsant urine test to help determine if a patient's body is rejecting a kidney transplant.

During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.

The firms will use Resolution's ctDx liquid biopsy technology to find non-small cell lung cancer patients who may benefit from Mirati's KRAS G12C inhibitor therapy.

Ravgen has alleged that several leading NGS-based non-invasive prenatal testing and oncology assays infringe two patents held by the firm.

CareDx first sued Natera in March 2019 for infringing two of its patents, then amended the suit a year later to add a third patent.

The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The randomized, Phase II trial will test ctDNA-guided second-line adjuvant therapy for stage II and III hormone receptor-positive, HER-2 negative breast cancer.

Pages